Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Means Investment CO. Inc.

Means Investment CO. Inc. raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,040 shares of the company’s stock after buying an additional 9,508 shares during the period. Means Investment CO. Inc.’s holdings in Hims & Hers Health were worth $1,210,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Ausbil Investment Management Ltd acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at $127,000. Genesee Capital Advisors LLC acquired a new position in shares of Hims & Hers Health during the fourth quarter worth about $889,000. Perigon Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $337,000. Pacer Advisors Inc. acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $374,000. Finally, KBC Group NV raised its holdings in shares of Hims & Hers Health by 107.9% during the 4th quarter. KBC Group NV now owns 8,471 shares of the company’s stock valued at $205,000 after buying an additional 4,396 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. This represents a 73.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,256,067 shares of company stock worth $34,459,485 over the last ninety days. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $37.33 on Monday. The company has a market cap of $8.16 billion, a PE ratio of 84.85 and a beta of 1.35. Hims & Hers Health, Inc. has a 12 month low of $8.51 and a 12 month high of $37.96. The company has a fifty day moving average price of $29.20 and a two-hundred day moving average price of $22.57.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Piper Sandler upped their price target on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Needham & Company LLC raised their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.